These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30269155)

  • 1. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.
    Pfannenberg C; Gueckel B; Wang L; Gatidis S; Olthof SC; Vach W; Reimold M; la Fougere C; Nikolaou K; Martus P
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):54-64. PubMed ID: 30269155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
    J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study.
    Reinert CP; Sekler J; la Fougère C; Pfannenberg C; Gatidis S
    Eur Radiol; 2020 Mar; 30(3):1325-1333. PubMed ID: 31728688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
    Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
    J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
    Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
    J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
    J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
    Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
    J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hanna L; Stine SH; Coleman RE
    Cancer; 2009 Jan; 115(2):410-8. PubMed ID: 19016303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
    J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PET/CT on management of patients with esophageal cancer - results from a PET/CT registry study.
    Reinert CP; Sekler J; Gani C; Nikolaou K; la Fougère C; Pfannenberg C; Gatidis S
    Eur J Radiol; 2021 Mar; 136():109524. PubMed ID: 33434862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Metser U; Dudebout J; Baetz T; Hodgson DC; Langer DL; MacCrostie P; Mak V; Tau N
    Cancer; 2017 Aug; 123(15):2860-2866. PubMed ID: 28295218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The National Oncologic PET Registry (NOPR): design and analysis plan.
    Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
    J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
    Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
    Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.
    Hillner BE; Tunuguntla R; Fratkin M
    J Clin Oncol; 2004 Oct; 22(20):4147-56. PubMed ID: 15483025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
    J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intended Versus Inferred Treatment After
    Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
    J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of hybrid PET-CT scan on overall oncologic management, with a focus on radiotherapy planning: a prospective, blinded study.
    Kruser TJ; Bradley KA; Bentzen SM; Anderson BM; Gondi V; Khuntia D; Perlman SB; Tome WA; Chappell RJ; Walker WL; Mehta MP
    Technol Cancer Res Treat; 2009 Apr; 8(2):149-58. PubMed ID: 19334796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
    Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
    J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
    You JJ; Cline KJ; Gu CS; Pritchard KI; Dayes IS; Gulenchyn KY; Inculet RI; Dhesy-Thind SK; Freeman MA; Chan AM; Julian JA; Levine MN
    Br J Cancer; 2015 May; 112(11):1737-43. PubMed ID: 25942398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
    Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
    Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.